Kahlert CR, et al. - In this proof-of-concept study, researchers aimed at determining the feasibility and efficacy of NVP plus Lamivudine (3TC) as novel simplified HIV maintenance dual therapy (DT) strategy. Twenty cases receiving combined antiretroviral treatment (cART) and with fully suppressed HIV plasma viral load > 24 months–whereof > 6 months on an NVP- containing regimen—were switched to oral NVP plus 3TC for 24 weeks. Decision was then left on patients concerning whether to continue DT or return to the previous cART. After a total of 144 observation weeks, no failure was recorded in any of the patients. Further there was no difference in the frequency of low- level HIV-RNA detection from the period before randomization. Findings thereby suggest this dual HIV maintenance strategy as feasible and effective. Although the findings are surprising, the results do not support the use of this dual regimen because of the nature of a proof-of-concept study.